ClinicalTrials.gg
CompletedNCT07578636Updated Sep 21, 2026

A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

A Phase 1 interventional study of Oral [14C] PF-07799544 and Oral Unlabeled PF-07799544 in Healthy Male Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

For this study, the study medicine has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicine appears in the blood, urine, and stool after it is given. This type of study is called a radiolabeled study.

The purpose of this radiolabeled study is to learn how a certain amount of [14C] PF-07799544 is taken up into the bloodstream and removed from the body.

The study is seeking participants who are:

Male Ages 18 to 55 years of age confirmed to be healthy based on medical and physical tests.

Weigh more than 50 kilograms (kg) and have a body mass index of 17.5 to 32 kg per meter squared.

The study consists of two parts. In part one, all participants will receive one full dose of [14C]PF-07799544 by mouth.

Part two will begin at least 14 days after the dose in part one. In part two, participants will receive one full dose of PF-07799544 by mouth and one small dose of [14C] PF-07799544 by intravenous (IV) infusion. IV infusion will be directly injected into the veins.

To understand how the medicine is processed in the body, samples of blood, urine, feces, and vomit (if any) will be collected after each dose is given. This will help understand:

How much PF-07799544 is taken up into the bloodstream when taken by mouth compared to the dose given by IV How the body removes it from the blood steam. Participants will take part in the study for about 7 weeks, including evaluation at the start and follow-up period.

Read the detailed description

Not Provided.

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Males 18 to 55years of age, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead ECGs.

of 17.5-32 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing.

Previous administration of an product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.

Total 14C radioactivity measured in plasma should not exceed 2.5 × standard biological carbon ratio.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive one dose of \[14C\] PF-07799544 by mouth in Period 1. After a washout, participants will receive one dose of PF-07799544 by mouth and one intravenous (IV) infusion of \[14C\] PF-07799544 in Period 2

    Drug: Oral [14C] PF-07799544 · Drug: Oral Unlabeled PF-07799544 · Drug: IV [14C] PF-07799544

Interventions

  • A single oral dose of \[14C\] PF-07799544 will be administered as an extemporaneous suspension in Period 1.

  • DrugOral Unlabeled PF-07799544

    A single oral dose of unlabeled PF-07799544 will be administered as extemporaneous solution in Period 2.

  • A single IV infusion of \[14C\] PF-07799544 will be administered at the approximate Tmax after administration of the unlabeled oral dose of PF-07248144 in Period 2.

06

What researchers measure

Primary outcomes

  1. Total recovery (%) of radioactivity in urine, feces and vomitus (if any), expressed as a percent of total oral radioactive dose administered.

    To characterize the extent of excretion of total radioactivity in urine, feces and vomitus (if any) following administration of a single oral dose of \[14C\]PF-07799544.

    Time frame: Period 1 pre-dose to maximum days 15

  2. Metabolic profiling/identification and determination of relative abundance of [14C]PF-07799544 and the metabolites of PF-07799544 in plasma, urine and feces, if possible.

    To characterize the metabolic profile and identify the circulating and excreted metabolites of PF- 07799544 following administration of a single oral dose of \[14C\]PF-07799544.

    Time frame: Period 1 pre-dose to maximum days 15

Secondary outcomes

  1. The ratio of dose-normalized AUCinf (if data permit, otherwise AUClast) of oral PF-07799544 to IV [14C]PF-07799544.

    To determine the oral absolute bioavailability (F) of PF-07799544 from a single oral dose of PF-07799544 compared to a single IV microtracer of \[14C\]PF-07799544.

    Time frame: Period 2 pre-dose to maximum days 6.

  2. The ratio of total recovered radioactivity 14C in urine following single dose administration of [14C]PF-07799544 orally in Period 1 and IV microtracer, microdose administration of [14C]PF-07799544 in Period 2.

    To determine the fraction of PF-07799544 dose absorbed (Fa) from a single oral dose of \[14C\]PF-07799544.

    Time frame: Period 1 pre-dose to maximum days 15; Period 2 pre-dose to maximum days 6.

  3. Number of Participants With Treatment Emergent Adverse Events.

    To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544.

    Time frame: Baseline up to 28 to 35 days post last study intervention dose.

  4. Number of Participants with Treatment Emergent Clinically Significant Laboratory Abnormalities.

    To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544.

    Time frame: Baseline up to 28 to 35 days post last study intervention dose.

  5. Number of Participants With Treatment Emergent Clinically Significant Abnormal Vital Signs.

    To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544.

    Time frame: Baseline up to 28 to 35 days post last study intervention dose.

  6. Number of Participants With Treatment Emergent Clinically Significant Physical Examination Abnormalities.

    To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544.

    Time frame: Baseline up to 28 to 35 days post last study intervention dose.

  7. Number of Participants With Treatment Emergent Clinically Significant Abnormal ECG Measurements.

    To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544.

    Time frame: Baseline up to 28 to 35 days post last study intervention dose.

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jul 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
May 18, 2026
Primary completionActual
Jul 2, 2026
CompletionActual
Aug 15, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578636
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 11, 2026
Start date
May 18, 2026
Primary completion
Jul 2, 2026
Completion
Aug 15, 2026
Last update
Sep 21, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Polfurmetinib

Start the discussion